# IRADIMED CORPORATION (IRMD) FY2026 Q2 Balance Sheet

- Company: IRADIMED CORPORATION (IRMD)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-31, accession number 0001628280-26-051402
- Page: https://plicit.ai/financials/irmd/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/irmd-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 114,975,000 US dollars
- **Current assets**: 86,722,000 US dollars
- **Non-current assets**: 28,253,000 US dollars
- **Liabilities**: 13,227,000 US dollars
- **Current liabilities**: 9,164,000 US dollars
- **Non-current liabilities**: 4,063,000 US dollars
- **Equity**: 101,748,000 US dollars
- **Cash and cash equivalents**: 59,080,000 US dollars
- **Accounts receivable, net of allowance for credit losses of $174,138 as of June 30, 2026, and $190,686 as of December 31, 2025**: 13,192,000 US dollars
- **Inventory, net**: 12,257,000 US dollars
- **Prepaid expenses and other current assets**: 1,401,000 US dollars
- **Prepaid income taxes**: 792,000 US dollars
- **Property and equipment, net**: 24,208,000 US dollars
- **Intangible assets, net**: 3,438,000 US dollars
- **Deferred tax asset, net**: 363,000 US dollars
- **Other assets**: 244,000 US dollars
- **Deferred revenue**: 3,469,000 US dollars
- **Accrued payroll and benefits**: 3,059,000 US dollars
- **Accounts payable**: 1,849,000 US dollars
- **Other accrued taxes**: 641,000 US dollars
- **Warranty reserve**: 146,000 US dollars
- **Accrued income taxes**: 0 US dollars
- **Deferred revenue, non-current**: 4,063,000 US dollars
- **Retained earnings**: 70,154,000 US dollars
- **Additional paid-in capital**: 31,593,000 US dollars
- **Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,786,740 shares issued and outstanding as of June 30, 2026, and 12,781,774 shares issued and outstanding as of December 31, 2025**: 1,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.